Clinical Trials Browser

Phase 1 × Recruiting × CTLA-4 Antigen × Clear all

NCT06508463 2026-03-16

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase 1 Recruiting

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Phase 1 Recruiting

Melanoma

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT04003649 2025-07-10

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Phase 1 Recruiting

Glioblastoma

NCT06399419 2024-05-30

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Phase 1 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell